Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of BZ371B in ARDS Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* Men or Women~* In Mechanical Ventilation~* Diagnosed with Acute Respiratory Dystress Syndrome characterized by: acute beginning (less than one week from the beggining of the disease); bilateral opacity in the Torax X-Ray (not explained by stroke, atelectasis or nodules); respiratory failure not derived from cardiac failure and water overload.~* P/F lower or equal to 150 mmHg with FiO2 higher or equal to 70% and PEEP higher or or equal to 88 mmHg~* ALready executed first pronation, followed by supine position. One hour after returning from supine position.~Exclusion Criteria:~* Presence of pulmonary thromboembolism~* Presence of secondary bacterial pneumonia~* Severe Asthma~* Pregnant or lactanting women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated Group (Type: EXPERIMENTAL): Intubated patients treated with inhaled BZ371B will receive a dose of 12 mg of BZ371B divided in two different nebulizations per day, for three cosnecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).